For many investors, the main point of stock picking is to generate higher returns than the overall market. But if ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships in 2025. Click for this ARQT update.

Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

Beam Therapeutics Inc . (NASDAQ:BEAM), a $2.1 billion market cap pioneer in the field of precision genetic medicines through base editing, is set to present new data from its ongoing BEACON Phase 1/2 ...

Pfizer is approaching a whole new era of growth after launching a record number of new products and putting a focus on its ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

GE Aerospace reported better-than-expected fourth-quarter earnings on Thursday. GE Aerospace reported fourth-quarter sales of $9.9 billion, operating profit of $1.9 billion, and earnings per share of ...

People take pictures on an overpass with a display of stock information in front of buildings in the Lujiazui financial district in Shanghai, China August 6, 2024. REUTERS/Nicoco Chan/File photo ...

On Monday the company closed a US$996 million ($1.6bn) loan, including US$968m in principal and US$28m of capitalised interest, a US$268m mark up from a conditional loan announced for its Rhyolite ...